Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis

CONCLUSION: Lasmiditan demonstrated efficacy as abortive therapy for episodic migraine with central nervous system-related side effects.

Source: Indian Journal of Pharmacology - January 31, 2023 Category: Drugs & Pharmacology Authors: Marya Ahsan Ayaz Khurram Mallick Source Type: research